Xintela AB

Xintela AB

  • Price (SEK)0.4725
  • Today's Change-0.017 / -3.37%
  • Shares traded114.11k
  • 1 Year change-64.29%
  • Beta1.3349
Data delayed at least 15 minutes, as of Feb 03 2023 17:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Xintela AB (Xintela) is a Sweden-based biomedical company engaged in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumors. In the field of regenerative medicine, the Company focuses on cartilage damage and osteoarthritis, and in the field of brain tumors, its focuses on the development of a treatment for glioblastoma, an aggressive tumor. The Company has developed therapeutic antibodies, which bind to cancer cells. It has also developed XINMARK, a marker technology which consists of specific proteins, which work as recognition flags on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-78.22m
  • Incorporated2009
  • Employees--
  • Location
    Xintela ABScheeletorget 1LUND 223 81SwedenSWE
  • Phone+46 462756500
  • Websitehttp://xintela.se/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Lipum AB (publ)0.00-54.24m107.16m----23.78-----11.98-11.980.000.58860.00-------144.61---166.87--------------0.3449---100.00---147.69------
Nordic Nanovector ASA0.00-447.70m109.49m40.00--0.5816-----4.20-,940.80----0.00-------5.81---29.60--
Bioextrax AB publ545.90k-15.78m109.84m----4.44--201.22-1.01-1.010.03470.9710.0332--3.26---95.97---123.03---86.52---2,890.40-----22,539.960.00--1,166.12---89.02------
Scandion Oncology A/S-100.00bn-100.00bn117.51m----0.8982----------3.21----------------------------0.0072-------217.81------
Isofol Medical AB (publ)15.65m-195.59m124.37m15.00--0.6766--7.95-4.22-4.220.1241.140.0441--1.171,043,000.00-55.10-61.04-69.25-74.66-1,086.11---1,250.18-1,186.01----0.0023---39.63---5.96------
Alzinova AB0.00-10.81m129.68m----1.18-----0.4388-0.43880.003.400.00-------10.34-8.30-10.66-8.62-----------476.840.00-------16.19--28.46--
Toleranzia AB0.00-8.14m130.17m----1.07-----0.0673-0.06730.001.100.00-------6.19-12.63-6.43-13.30------------0.0069-------27.68--55.48--
Peptonic Medical AB36.14m-73.58m135.94m----0.7808--3.76-0.2277-0.22770.10750.14350.41881.043.39---85.26-38.78-113.84-45.5560.91---203.61-223.580.5254-38.840.2223---10.10---115.39---16.66--
2cureX AB8.00k-28.86m137.30m----2.71--17,162.84-1.76-1.760.00052.880.0001--0.0011---42.42-23.18-44.73-27.65-176,600.00-88,517.02-360,787.50-94,872.34----0.00-------158.70---37.81--
Coegin Pharma AB0.00-35.59m137.68m----5.64-----0.0516-0.05160.000.02640.00-------142.04---158.13-------------1,546.570.00------41.29------
Xintela AB0.00-78.22m145.33m-----------0.5315-0.53150.00-0.00850.00-------302.11-119.65-559.20-180.99-------12,122.000.3763-17.76---------19.76--27.36--
Aqua Bio Technology ASA1.66m-23.41m152.86m2.00--19.50--91.98-1.13-1.130.08040.36770.06440.66061.50---90.75-73.71-152.91-100.31-117.42-41.86-1,408.30-2,046.060.3127-12.490.4955--250.98---33.32--56.78--
StenoCare A/S2.51m-27.22m166.31m----3.97--66.21-1.53-1.530.14112.350.0389--3.01---42.17---44.49-------1,083.68--2.77-26.150.2065--854.55---8.03------
AroCell AB (publ)30.41m-62.15m169.09m----0.7073--5.56-0.3854-0.38540.1641.040.12244.768.63---25.27-32.88-26.58-35.44-15.37-37.34-206.39-966.137.41-20,923.000.00--14,180.95194.00-107.99---47.95--
New Nordic Healthbrands AB496.85m-3.79m170.99m37.00--1.47--0.3441-0.6121-0.612180.2018.741.954.133.96---1.4913.05-3.0725.3611.7917.56-0.76325.290.9924-1.860.308238.8714.3910.9819.9217.3535.3325.59
Combigene AB105.40m63.23m175.64m--2.781.072.671.673.193.195.328.290.764--9.52--45.84-19.2947.74-24.55----60.00-55.8524.54--0.00------171.35------
Data as of Feb 03 2023. Currency figures normalised to Xintela AB's reporting currency: Swedish Krona SEK
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.